Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2006

Solexa Secures Two-Year Equity Financing Commitment

  • Solexa secured a two-year commitment for up to $75 million in a common stock equity financing from Azimuth Opportunity. Solexa intends to use the net proceeds from the financing for the development and commercialization of the Solexa Genome Analysis System, working capital, and other general corporate purposes.

    During the term of this commitment, Solexa may sell registered shares of its common stock to Azimuth at a small discount to the market price. Solexa will determine the timing and amount of any sales of its stock.

    The shares are being offered pursuant to an effective registration statement filed with the SEC.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »